Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

13.73 -0.46 (-3.21%)
Streaming Delayed Price Updated: 10:51 AM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Takeda Named Global Top Employer for Sixth Consecutive Year
From Takeda Pharmaceutical Company Limited
Via Business Wire
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch... 
Via Talk Markets
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
From Takeda Pharmaceutical Company Limited
Via Business Wire
A Bullish Sign Appears On Takeda Pharmaceutical's Chart
Via Benzinga
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
Via Benzinga
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
Via Benzinga
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Via Benzinga
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
Via Benzinga
Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies
Via Benzinga
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
From Takeda Pharmaceutical Company Limited
Via Business Wire
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study  
Via Benzinga
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
From Takeda Pharmaceutical Company Limited
Via Business Wire
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
From Singapore Economic Development Board (EDB)A*STAR
Via ACN Newswire
Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?
Tech layoffs are in the news, but life sciences companies seem to be doing better. 
Via The Motley Fool
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
The company says it plans soon to present Phase 2 results and its Phase 3 study design. 
Via Investor's Business Daily
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
From Takeda Pharmaceutical Company Limited
Via Business Wire
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result... 
Via Benzinga
Why Puma Biotechnology's Shares Jumped 20% on Monday
It may have benefited from positive news about another company's drug candidate. 
Via The Motley Fool
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
Via Benzinga
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
From Takeda Pharmaceutical Company Limited
Via Business Wire
2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade
Is now the time to load up on these high-yielding investments? 
Via The Motley Fool
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close. 
Via The Motley Fool
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
From Takeda Pharmaceutical Company Limited
Via Business Wire
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
7 Dividend Stocks to Sell Pronto Before a Painful Downturn
Investors may find many dividend stocks to sell, considering returns from the risk-free U.S. Treasury Bills often exceed their yield. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.